Mitigate risks for clinicians and patients
Expert-backed testing to monitor therapy, assess risk, and identify misuse
Controlled substances are widely prescribed for a number of clinical indications; however, these substances have a high risk for misuse and diversion. To help clinicians manage the challenges of abuse presented by controlled substances, the American Association for Clinical Chemistry Academy developed Laboratory Medicine Practice Guidelines that recommend using clinical laboratory tests to monitor drug therapy in pain management patients.
The Clinical and Forensic Toxicology Laboratory at Mayo Clinic offers the industry’s most comprehensive evidence-based urine drug testing menu. Our profiles were developed with consistency to practice guidelines and help clinicians identify specific prescription drugs, adulterants, and illicit substances. Our screening and monitoring assays employ a variety of methodologies that capitalize on emerging technologies to offer the highest level of testing across the spectrum of controlled substances for precision insights on patients’ drug use.
Pain management is among the most common legitimate uses for controlled substance therapy. Our streamlined approach to controlled substance monitoring ensures accurate results through validity testing and interpretive reports. Learn more about Mayo Clinic Laboratories’ Pain Management testing services.
By the numbers
combining clinical UDT with other risk-mitigation strategies can reduce substance misuse by at least 50%1
million people misused prescriptions in 20192
people died every day from overdose, including opioids3
Our comprehensive profiles
Please note: If the limited immunoassay screen is positive in this profile (Mayo ID: CSMPU), confirmation with quantification of presumptive positives for barbiturates, cocaine and metabolites, and/or tetrahydrocannabinol metabolite will be performed at an additional charge. If the quantification of presumptive positive results is not required, refer to Controlled Substance Monitoring Hybrid Drug Profile, High-Resolution Mass Spectrometry, and Immunoassay Screen, Random, Urine (Mayo ID: CSMHU)
Our targeted screening profiles
*To better meet the needs of our clients’, this profile is available with the quantification of presumptive positive results (Mayo Test ID: CSMPU) or without (Mayo Test ID: CSMHU) for the drug classes screened by immunoassay (i.e., barbiturates, cocaine, and THC).
**Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are direct biomarkers of ethanol and are detectable in urine for up to five days following alcohol consumption. EtG/EtS results should be interpreted in the context of all available clinical and behavioral information.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the use of qualitative urine screening assays and quantitative confirmatory testing to determine compliance in pain management patients.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted stimulant and PCP screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed CNS stimulant medications.
Controlled substance testing options vary in the details they provide about patient drug use, painting an incomplete picture of usage patterns that can hinder accurate prescription monitoring and treatment outcomes. However, a new comprehensive Controlled Substance Monitoring Panel, developed by the Clinical and Forensic Toxicology Laboratory at Mayo Clinic Laboratories, offers in-depth analysis on more than 70 different prescription medications and illicit substances to provide clinicians with details and interpretations on patients’ controlled substance use lacking in other laboratory assays.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted opioid screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed opioid pain-relieving medication.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., will highlight Mayo Clinic’s new targeted benzodiazepine assay and discuss the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.